keyword
Keywords patient derived xenograft meta...

patient derived xenograft metastasis

https://read.qxmd.com/read/38659028/azgp1-deficiency-promotes-angiogenesis-in-prostate-cancer
#1
JOURNAL ARTICLE
Ru M Wen, Zhengyuan Qiu, G Edward W Marti, Eric E Peterson, Fernando Jose Garcia Marques, Abel Bermudez, Yi Wei, Rosalie Nolley, Nathan Lam, Alex LaPat Polasko, Chun-Lung Chiu, Dalin Zhang, Sanghee Cho, Grigorios Marios Karageorgos, Elizabeth McDonough, Chrystal Chadwick, Fiona Ginty, Kyeong Joo Jung, Raghu Machiraju, Parag Mallick, Laura Crowley, Jonathan R Pollack, Hongjuan Zhao, Sharon J Pitteri, James D Brooks
BACKGROUND: Loss of AZGP1 expression is a biomarker associated with progression to castration resistance, development of metastasis, and poor disease-specific survival in prostate cancer. However, high expression of AZGP1 cells in prostate cancer has been reported to increase proliferation and invasion. The exact role of AZGP1 in prostate cancer progression remains elusive. METHOD: AZGP1 knockout and overexpressing prostate cancer cells were generated using a lentiviral system...
April 24, 2024: Journal of Translational Medicine
https://read.qxmd.com/read/38651826/mutant-ras-driven-secretome-causes-skeletal-muscle-defects-in-breast-cancer
#2
JOURNAL ARTICLE
Ruizhong Wang, Aditi S Khatpe, Brijesh Kumar, Henry Elmer Mang, Katie Batic, Adedeji K Adebayo, Harikrishna Nakshatri
Cancer-induced skeletal muscle defects differ in severity between individuals with the same cancer type. Cancer subtype-specific genomic aberrations are suggested to mediate these differences, but experimental validation studies are very limited. We utilized three different breast cancer patient-derived xenograft (PDX) models to correlate cancer subtype with skeletal muscle defects. PDXs were derived from brain metastasis of triple negative breast cancer (TNBC), Estrogen Receptor-positive/Progesterone Receptor-positive (ER+/PR+) primary breast cancer from a BRCA2-mutation carrier, and pleural effusion from an ER+/PR- breast cancer...
April 23, 2024: Cancer Res Commun
https://read.qxmd.com/read/38645554/surufatinib-combined-with-photodynamic-therapy-induces-ferroptosis-to-inhibit-cholangiocarcinoma-in-vitro-and-in-tumor-models
#3
JOURNAL ARTICLE
Yun-Peng Huang, Yong-Xiang Wang, Hui Zhou, Zhong-Tao Liu, Zi-Jian Zhang, Li Xiong, Heng Zou, Yu Wen
The curative effect of single therapy for advanced cholangiocarcinoma (CCA) is poor, thus investigating combined treatment strategies holds promise for improving prognosis. Surufatinib (SUR) is a novel multikinase inhibitor that has been confirmed to prolong survival of patients with advanced CCA. Photodynamic therapy (PDT) can also ablate advanced CCA and relieve biliary obstruction. In this study, we explored the anti-CCA effect of SUR combined with PDT, and explored the underlying mechanism. We found that SUR could effectively inhibit the abilities of proliferation, migration and metastasis in CCA cells (HUCCT-1, RBE)...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38587398/establishment-of-patient-derived-xenograft-mouse-model-with-human-osteosarcoma-tissues
#4
JOURNAL ARTICLE
Xingyuan Sun, Junli Chang, Chujie Zhou, Peng Zhao, Suxia Guo, Junjie Tong, Yongjun Wang, Yanping Yang
Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. Despite the development of new treatment plans in recent years, the prognosis for osteosarcoma patients has not significantly improved. Therefore, it is crucial to establish a robust preclinical model with high fidelity. The patient-derived xenograft (PDX) model faithfully preserves the genetic, epigenetic, and heterogeneous characteristics of human malignancies for each patient. Consequently, PDX models are considered authentic in vivo models for studying various cancers in transformation studies...
March 22, 2024: Journal of Visualized Experiments: JoVE
https://read.qxmd.com/read/38554771/nanodrug-modified-with-engineered-cell-membrane-targets-cdks-to-activate-apd-l1-immunotherapy-against-liver-metastasis-of-immune-desert-colon-cancer
#5
JOURNAL ARTICLE
Dongbing Ding, Rongpu Liang, Tan Li, Tianyun Lan, Yiquan Li, Shengxin Huang, Guanhui He, Jiannan Ren, Weibo Li, Zongheng Zheng, Tufeng Chen, Jiafeng Fang, Lijun Huang, Xintao Shuai, Bo Wei
Immunotherapy based on the PD-1/PD-L1 axis blockade has no benefit for patients diagnosed with colon cancer liver metastasis (CCLM) for the microsatellite stable/proficient mismatch repair (MSS/pMMR)) subtype, which is known as an immune-desert cancer featuring poor immunogenicity and insufficient CD8+ T cell infiltration in the tumor microenvironment. Here, a multifunctional nanodrug carrying a cyclin-dependent kinase (CDK)1/2/5/9 inhibitor and PD-L1 antibody is prepared to boost the immune checkpoint blockade (ICB)-based immunotherapy against MSS/pMMR CCLM via reversing the immunosuppressive tumor microenvironment...
March 28, 2024: Journal of Controlled Release
https://read.qxmd.com/read/38529509/overcoming-brain-derived-therapeutic-resistance-in-her2-breast-cancer-brain-metastasis
#6
Danyyl Ippolitov, Yi-Han Lin, Jeremy Spence, Aleksandra Glogowska, Thatchawan Thanasupawat, Jason Beiko, Marc R Del Bigio, Xin Xu, Amy Wang, Raul Calvo, Abhijeet Kapoor, Juan J Marugan, Mark J Henderson, Thomas Klonisch, Sabine Hombach-Klonisch
Brain metastasis of HER2+ breast cancer occurs in about 50% of all women with metastatic HER2+ breast cancer and confers poor prognosis for patients. Despite effective HER2-targeted treatments of peripheral HER2+ breast cancer with Trastuzumab +/-HER2 inhibitors, limited brain permeability renders these treatments inefficient for HER2+ breast cancer brain metastasis (BCBM). The scarcity of suitable patient-derived in-vivo models for HER2+ BCBM has compromised the study of molecular mechanisms that promote growth and therapeutic resistance in brain metastasis...
February 22, 2024: bioRxiv
https://read.qxmd.com/read/38514606/the-eif3h-hax1-axis-increases-raf-mek-erk-signaling-activity-to-promote-colorectal-cancer-progression
#7
JOURNAL ARTICLE
Huilin Jin, Xiaoling Huang, Qihao Pan, Ning Ma, Xiaoshan Xie, Yue Wei, Fenghai Yu, Weijie Wen, Boyu Zhang, Peng Zhang, Xijie Chen, Jie Wang, Ran-Yi Liu, Junzhong Lin, Xiangqi Meng, Mong-Hong Lee
Eukaryotic initiation translation factor 3 subunit h (EIF3H) plays critical roles in regulating translational initiation and predicts poor cancer prognosis, but the mechanism underlying EIF3H tumorigenesis remains to be further elucidated. Here, we report that EIF3H is overexpressed in colorectal cancer (CRC) and correlates with poor prognosis. Conditional Eif3h deletion suppresses colorectal tumorigenesis in AOM/DSS model. Mechanistically, EIF3H functions as a deubiquitinase for HAX1 and stabilizes HAX1 via antagonizing βTrCP-mediated ubiquitination, which enhances the interaction between RAF1, MEK1 and ERK1, thereby potentiating phosphorylation of ERK1/2...
March 21, 2024: Nature Communications
https://read.qxmd.com/read/38499286/reversal-of-cisplatin-resistance-in-oral-squamous-cell-carcinoma-by-piperlongumine-loaded-smart-nanoparticles-through-inhibition-of-hippo-yap-signaling-pathway
#8
JOURNAL ARTICLE
Pratikshya Sa, Priya Singh, Sudhakar Panda, Rajeeb K Swain, Rupesh Dash, Sanjeeb Kumar Sahoo
Cisplatin alone or in combination with 5FU and docetaxel is the preferred chemotherapy regimen for advanced-stage OSCC patients. However, its use has been linked to recurrence and metastasis due to the development of drug resistance. Therefore, sensitization of cancer cells to conventional chemotherapeutics can be an effective strategy to overcome drug resistance. Piperlongumine, an alkaloid, have shown anticancer properties and sensitizes numerous neoplasms, but its effect on OSCC has not been explored. However, low aqueous solubility and poor pharmacokinetics limit its clinical application...
March 16, 2024: Translational Research: the Journal of Laboratory and Clinical Medicine
https://read.qxmd.com/read/38482238/regional-delivery-of-mesothelin-targeted-chimeric-antigen-receptor-t-cell-effectively-and-safely-targets-colorectal-cancer-liver-metastases-in-mice
#9
JOURNAL ARTICLE
Xin Zhou, Minjie Yang, Jiaze Yu, Jingwen Tan, Nan Xu, Yongjie Zhou, Wen Zhang, Jingqin Ma, Zihan Zhang, Alex Friedlaender, Justin Taylor, Lei Yu, Zhiping Yan
BACKGROUND: Liver metastasis is the major cause of colorectal cancer related death. Mesothelin (MSLN)-targeted chimeric antigen receptor (CAR) T-cell therapy has been illustrated effective and safe through regional delivery of breast cancer, ovarian cancer and malignant mesothelioma tumors. Herein, we investigated the safety, efficacy, and immune microenvironment of regional delivery of MSLN (CAR) T-cell in the treatment of colorectal carcinoma liver metastases (CRLM). METHODS: Second-generation MSLN CAR T-cells were administered by portal vein (PV) or caudal vein (CV, systemic administration) delivery in an orthotopic MSLN+ CRLM nonobese diabetic (NOD)/severe combined immunodeficient (SCID)/γc-/- (NSG) mouse model...
February 29, 2024: Journal of Gastrointestinal Oncology
https://read.qxmd.com/read/38480552/immunopet-ct-imaging-of-clear-cell-renal-cell-carcinoma-with-18-f-rccb6-a-first-in-human-study
#10
JOURNAL ARTICLE
Qianyun Wu, Yanfei Wu, You Zhang, Yihui Guan, Gang Huang, Fang Xie, Jianjun Liu, Wei Zhai, Weijun Wei
PURPOSE: The cluster of differentiation (CD70) is a potential biomarker of clear cell renal cell carcinoma (ccRCC). This study aims to develop CD70-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging tracers and explore the diagnostic value in preclinical studies and the potential value in detecting metastases in ccRCC patients. METHODS: Four novel CD70-specific single-domain antibodies (sdAbs) were produced and labelled with 18 F by the aluminium fluoride restrained complexing agent (AlF-RESCA) method to develop radiotracers...
March 14, 2024: European Journal of Nuclear Medicine and Molecular Imaging
https://read.qxmd.com/read/38476330/improving-the-predictive-accuracy-of-efficacy-evaluation-using-tumor-orthotopic-transplant-and-resection-model
#11
JOURNAL ARTICLE
Xiaoxi Li, Lingli Luo, Hui Qian
Preclinical efficacy evaluation and tumor drug sensitivity analysis are two main applications of efficacy evaluation. Preclinical efficacy evaluation is to predict whether candidate drugs or therapies may improve patient outcomes in clinical trials. Tumor drug sensitivity analysis is an approach for the personalized evaluation and optimization of approved anti-cancer drugs and treatment regimens. Overall survival (OS) is the gold standard to evaluate the outcome of drugs or therapies in both clinical trials and clinical treatment...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38470497/infiltrative-vessel-co-optive-growth-pattern-induced-by-iqgap3-overexpression-promotes-microvascular-invasion-in-hepatocellular-carcinoma
#12
JOURNAL ARTICLE
Miaoling Tang, Shuxia Zhang, Meisongzhu Yang, Rongni Feng, Jinbin Lin, Xiaohong Chen, Yingru Xu, Ruyuan Yu, Xinyi Liao, Ziwen Li, Xincheng Li, Man Li, Qiliang Zhang, Suwen Chen, Wanying Qian, Yuanji Liu, Libing Song, Jun Li
PURPOSE: Microvascular invasion (MVI) is a major unfavorable prognostic factor for intrahepatic metastasis and postoperative recurrence of hepatocellular carcinoma (HCC). However, the intervention and preoperative prediction for MVI remain clinical challenges due to the absent precise mechanism and molecular marker(s). Herein, we aimed to investigate the mechanisms underlying vascular invasion that can be applied to clinical intervention for MVI in HCC. EXPERIMENTAL DESIGN: The histopathological characteristics of clinical MVI+/HCC specimens were analyzed using multiplex immunofluorescence staining...
March 12, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38470224/nanomedicine-as-a-multimodal-therapeutic-paradigm-against-cancer-on-the-way-forward-in-advancing-precision-therapy
#13
REVIEW
Puja Sandbhor, Pranoti Palkar, Sakshi Bhat, Geofrey John, Jayant S Goda
Recent years have witnessed dramatic improvements in nanotechnology-based cancer therapeutics, and it continues to evolve from the use of conventional therapies (chemotherapy, surgery, and radiotherapy) to increasingly multi-complex approaches incorporating thermal energy-based tumor ablation ( e.g. magnetic hyperthermia and photothermal therapy), dynamic therapy ( e.g. photodynamic therapy), gene therapy, sonodynamic therapy ( e.g. ultrasound), immunotherapy, and more recently real-time treatment efficacy monitoring ( e...
March 12, 2024: Nanoscale
https://read.qxmd.com/read/38457248/quercetin-induced-degradation-of-rhoc-suppresses-hepatocellular-carcinoma-invasion-and-metastasis
#14
JOURNAL ARTICLE
Chunlong Huang, Weihua Lai, Shuai Mao, Deli Song, Jihong Zhang, Xiao Xiao
BACKGROUND: Tumor metastasis and recurrence are major causes of mortality in patients with hepatocellular carcinoma (HCC) that is still lack of effective therapeutic targets and drugs. Previous reports implied that ras homolog family member C (RhoC) plays a toxic role on metastasis and proliferation of cancer. METHODS: In this research, the correlation between RhoC and metastasis ability was confirmed by in vitro experiments and TCGA database. We explored whether quercetin could inhibit cell migration or invasion by transwell assay...
February 2024: Cancer Medicine
https://read.qxmd.com/read/38455101/vx-509-attenuates-the-stemness-characteristics-of-colorectal-cancer-stem-like-cells-by-regulating-the-epithelial-mesenchymal-transition-through-nodal-smad2-3-signaling
#15
JOURNAL ARTICLE
Yun Yuan, Xu-Fan Zhang, Yu-Chen Li, Hong-Qing Chen, Tian Wen, Jia-Lian Zheng, Zi-Yi Zhao, Qiong-Ying Hu
BACKGROUND: Colorectal cancer stem cells (CCSCs) are heterogeneous cells that can self-renew and undergo multidirectional differentiation in colorectal cancer (CRC) patients. CCSCs are generally accepted to be important sources of CRC and are responsible for the progression, metastasis, and therapeutic resistance of CRC. Therefore, targeting this specific subpopulation has been recognized as a promising strategy for overcoming CRC. AIM: To investigate the effect of VX-509 on CCSCs and elucidate the underlying mechanism...
February 26, 2024: World Journal of Stem Cells
https://read.qxmd.com/read/38454151/connectivity-mapping-based-identification-of-pharmacological-inhibitor-targeting-hdac6-in-aggressive-pancreatic-ductal-adenocarcinoma
#16
JOURNAL ARTICLE
Pranita Atri, Ashu Shah, Gopalakrishnan Natarajan, Satyanarayana Rachagani, Sanchita Rauth, Koelina Ganguly, Joseph Carmicheal, Dario Ghersi, Jesse L Cox, Lynette M Smith, Maneesh Jain, Sushil Kumar, Moorthy P Ponnusamy, Parthasarathy Seshacharyulu, Surinder K Batra
Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal due to limited therapeutic options and expensive/burdensome drug discovery processes. Utilizing genomic-data-driven Connectivity Mapping (CMAP) to identify a drug closer to real-world PC targeting may improve pancreatic cancer (PC) patient outcomes. Initially, we mapped CMAP data to gene expression from 106 PC patients, identifying nine negatively connected drugs. These drugs were further narrowed down using a similar analysis for PC cell lines, human tumoroids, and patient-derived xenografts datasets, where ISOX emerged as the most potent agent to target PC...
March 7, 2024: NPJ Precision Oncology
https://read.qxmd.com/read/38453889/targeting-metastasis-initiating-cancer-stem-cells-in-gastric-cancer-with-leukaemia-inhibitory-factor
#17
JOURNAL ARTICLE
Lornella Seeneevassen, Anissa Zaafour, Elodie Sifré, Coralie Genevois, Tra Ly Nguyen, Yasmine Pobiedonoscew, Alban Giese, Jérôme Guignard, Camille Tiffon, Benoit Rousseau, Anne-Aurélie Raymond, Geneviève Belleannée, Hélène Boeuf, Caroline Gronnier, Océane C B Martin, Julie Giraud, Philippe Lehours, Pierre Dubus, Christine Varon
Gastric cancer's (GC) bad prognosis is usually associated with metastatic spread. Invasive cancer stem cells (CSC) are considered to be the seed of GC metastasis and not all CSCs are able to initiate metastasis. Targeting these aggressive metastasis-initiating CSC (MIC) is thus vital. Leukaemia inhibitory factor (LIF) is hereby used to target Hippo pathway oncogenic members, found to be induced in GC and associated with CSC features. LIF-treated GC cell lines, patient-derived xenograft (PDX) cells and/or CSC tumourspheres underwent transcriptomics, laser microdissection-associated proteomics, 2D and 3D invasion assays and in vivo xenograft in mice blood circulation...
March 7, 2024: Cell Death Discovery
https://read.qxmd.com/read/38421864/generation-of-post-surgical-minimal-residual-disease-models-to-investigate-metastasis-in-soft-tissue-sarcoma-patient-derived-orthotopic-xenografts
#18
JOURNAL ARTICLE
Suzanne Fischer, David Creytens, Stefanie Gijsels, Benedicte Descamps, Lore Lapeire, An Hendrix, Gwen Sys, Olivier De Wever
Despite optimal multimodal treatment including surgical resection, 50%-80% of high-grade soft tissue sarcoma (STS) patients metastasize. Here, we present a protocol for the generation and use of post-surgical minimal residual disease models to investigate metastatic relapse in STS patient-derived xenografts. We describe steps for orthotopic engraftment of high-grade STS patient-derived tumor tissue. We then detail procedures for primary tumor resection with broad, negative resection margins and follow-up until metastases using MRI...
February 28, 2024: STAR protocols
https://read.qxmd.com/read/38407966/a-novel-synthesized-cyclohexane-hydroxytyrosol-derivative-suppresses-ovarian-cancer-cell-growth-through-inducing-ros-and-blocking-autophagic-flux
#19
JOURNAL ARTICLE
Guanfei Zhang, Min Wang, Yilin Gao, Aikaterini-Christina Komianou, Eleftheria A Georgiou, Yan Wang, Yezi Zheng, Jiankang Liu, Ioannis K Kostakis, Lin Zhao
AIMS: Drug resistance in ovarian cancer (OC) cells often leads to recurrence, metastasis, and high mortality rates among OC patients. Hydroxytyrosol (HT) has been reported to inhibit the proliferation of ovarian and other types of cancer cells. Here we synthesized a novel cyclohexane-hydroxytyrosol derivative (Chx-HT) for enhanced anticaner efficacy. We examined the growth-suppressing effect of Chx-HT on OC cells in vitro and in xenograft mouse model and investigated the underlying mechanism...
February 26, 2024: Antioxidants & Redox Signaling
https://read.qxmd.com/read/38407942/serpine2-promotes-liver-cancer-metastasis-by-inhibiting-c-cbl-mediated-egfr-ubiquitination-and-degradation
#20
JOURNAL ARTICLE
Shiyu Zhang, Xing Jia, Haojiang Dai, Xingxin Zhu, Wenfeng Song, Suchen Bian, Hao Wu, Shinuo Chen, Yangbo Tang, Junran Chen, Cheng Jin, Mengqiao Zhou, Haiyang Xie, Shusen Zheng, Penghong Song
BACKGROUND: Liver cancer is a malignancy with high morbidity and mortality rates. Serpin family E member 2 (SERPINE2) has been reported to play a key role in the metastasis of many tumors. In this study, we aimed to investigate the potential mechanism of SERPINE2 in liver cancer metastasis. METHODS: The Cancer Genome Atlas database (TCGA), including DNA methylation and transcriptome sequencing data, was utilized to identify the crucial oncogene associated with DNA methylation and cancer progression in liver cancer...
February 26, 2024: Cancer Communications
keyword
keyword
116022
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.